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 Abstract  
 
This paper provides a critical review of the prevalence of social phobia in European countries, a 
description of associated disability and burden and of clinical correlates and risk factors associated 
with social phobia. On the basis of a comprehensive literature search we identified 21 community 
studies and two primary care studies. The median lifetime and 12-month prevalence rates of social 
phobia in community samples referring to DSM-III-R and DSM-IV criteria were 6.65% and 2.0%, 
respectively. Younger individuals showed the highest rates, and women were more frequently affected 
than men. Social phobia was shown to be a persistent condition with a remarkably high degree of 
comorbid conditions, associated impairment and disability. Research deficits lie in a lack of data for 
most EU countries and in a lack of studies in children and the elderly. No data are available addressing 
met and unmet needs for intervention and costs, and data for vulnerability and risk factors of 
malignant course are scarce.   
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1. Introduction  
 
In the past, social phobia and various other conditions were grouped together under the term 
of neurotic disorders in DSM-II or ICD-9. Only two and a half decades ago, in DSM-III 
(APA, 1980), it was recognized as a single diagnostic category (ICD-10: F 40.1; WHO, 
1990). Since then, its significance as a highly impairing and persistent condition has been well 
documented. Also known as social anxiety disorder, social phobia is characterized by 
intensive fear reactions triggered by a wide variety of social situations, in which the person 
might be negatively evaluated by others. The anxiety is distinct and persistent, and it is often 
accompanied by disorder-specific bodily symptoms such as blushing, trembling, or sweating 
(Criterion A; DSM-IV; APA, 1994). When confronted with the feared situation, the individual 
immediately reacts with anxiety symptoms (Criterion B), whereas the person acknowledges 
that the fear is unreasonable and/or exaggerated (Criterion C). The anxiety leads to avoidance 
of the feared situations or to intensive discomfort when avoidance is not possible (Criterion 
D). The experience of anxiety and its symptoms, the anticipatory anxiety, and avoidance 
behaviour typically lead to distinct impairment in role functioning and to associated 
disabilities (Criterion E). To delineate temporary developmental social phobic syndromes 
from clinically significant social phobia, for individuals under 18 years of age, the symptoms 
have to persist for at least 6 months (Criterion F). Social phobia symptomatology can also 
occur as a more or less transient syndrome due to substance use and withdrawal syndrome, 
and potentially embarrassing medical conditions (e.g. trembling in Parkinson’s Disease, 
stuttering, or binge eating such as in eating disorders). Thus, to delineate social phobia from 
such substance and/or somatic condition-related syndromes, Criteria G and H from DSMIV 
require a series of differential diagnostic considerations. From the standpoint of 
epidemiological case finding methods, the latter differential diagnostic criteria as well as the 
impairment/distress criterion and the way they are translated in diagnostic interviews have 
been shown to be important sources of variation in prevalence estimates (Wittchen and Fehm, 
2003). Also note that, since the introduction of social phobia in the DSM-III (APA, 1980), the 
diagnostic criteria have been subject to changes, in an attempt to provide a sharper description 
of the disorder (e.g. with regard to the range of trigger situations). Consequently, 
corresponding changes in diagnostic assessment instruments and tools have had some 
influence on resulting prevalence estimates. In particular, the definition or operationalisation 
of impairment (see Criterion E) has been shown to be among the most important sources for 
variations in prevalence findings (Pélissolo et al., 2000), as cases of social phobia may differ 
in the degree of severity. Design factors such as sampling process, sample size, and age group 
composition are other important sources of variability.  
 
 
2. Aims  
 
Our main objective in this paper was to review critically epidemiological studies on the 
prevalence and/or incidence of social phobia in European union (EU) countries, with the 
focus on studies using DSM-III-R or DSM-IV definitions. An additional objective was to 
highlight important clinical correlates of social phobia (including risk factors, 
sociodemographic characteristics and cost and burden indicators), as revealed by 
epidemiological research.  
 
 
3. Methods  
 
Focusing on epidemiological studies in the community or services conducted in European 
countries (plus Iceland, Norway and Switzerland), we performed a comprehensive search of 
literature databases (Web of Science, Medline). Studies published since 1980 and using DSM-
III upwards diagnostic criteria were included. Search results were circulated among experts to 
supplement studies that were not identified and to include reports accepted for publication as 
well as unpublished data, if accessible. Results were also compared with search results of the 
European Brain Council (EBC) project group in Dresden (see Wittchen and Jacobi, 2005).  
 
 
4. Results  
 
4.1. Prevalence studies  
 
As shown in Table 1, a considerable number of community studies is available (n =21), the 
majority targeting the adult general population. Two studies have examined social phobia in 
primary care samples. Nearly all were cross-sectional prevalence studies; only two were 
longitudinal studies providing some information about incidence patterns (Wittchen et al., 
1999a, Merikangas et al., 2002). At first sight, these studies reveal a considerable degree of 
variation in terms of prevalence estimates. As noted above, a large part of this variation can 
be attributed to changes in the diagnostic criteria and to the instrument used in the respective 
study. Therefore, we discuss these findings according to the time when the study was 
conducted.  
 
Early (pre-1990) studies based on DSM-III revealed– consistent with US American studies–
fairly low lifetime prevalence estimates ranging between 1% and 4% (Degonda and Angst, 
1993; Faravelli et al., 1989; Lindal and Stefansson, 1993, Wittchen et al., 1992). These 
initially low estimates were largely attributed to the fact that the diagnostic instruments used 
did not examine the condition in a separate diagnostic module, which possibly resulted in an 
underestimation of the true prevalence (Wittchen et al., 1999b).  
 
Subsequent studies relying on the revised DSM-III-R criteria and expanded diagnosis-specific 
modules revealed considerably higher lifetime prevalence rates for social phobia ranging 
between 4.1% (Lépine and Lellouch, 1995) and 16% (Wacker et al., 1992). It is noteworthy 
that the authors of the Swiss study also reported a considerably lower ICD-10-based estimate 
of 9.5%–despite using the same sample and instrument–without revealing where this 
divergence comes from. The probably most frequently cited international DSM-III-R 
prevalence estimate has been 13.3%, as determined by the National Comorbidity Survey for 
the US adult population (Kessler et al., 1994; Magee et al., 1996).  
 
Whereas the DSM-III criteria for social phobia were revised profoundly, only minor 
differences exist between the DSM-III-R and DSM-IV definitions. The DSM-IV assessment 
tools, however, were revised addressing more comprehensively social trigger situations as 
well as impairment issues. The lifetime prevalence in adult samples, when modern diagnostic 
criteria were used, ranged from 3.9% in Belgium (Ansseau et al., 1999) to 13.7% in Norway 
(Kringlen et al., 2001); the median was 6.65%. Twelvemonth prevalence ranged from 0.6% 
(Spain) to 7.9% (Norway), and the median was 2.0%. Prevalence estimates were generally 
higher in women than in men. In few studies, shorter (≤1 month) prevalence periods have 
been reported, but these estimates varied between 1% and 15.6%.  
 
Table 1 also signals that only few EU countries, namely Belgium, France, Germany, Italy, the 
Netherlands, Spain and Sweden, have ever published any prevalence rates for community 
samples and a sizable age range. Further noteworthy issues are: (i) A small number of studies 
have been conducted using ICD-10 criteria for social phobia. (ii) In addition to community 
surveys, some surveys have also been conducted in general health care settings. In this 
domain, Szádóczky et al. (1997), who used the Diagnostic Interview Schedule (version III; 
DSM-III-R), reported a 4.9% 12-month prevalence rate in Hungarian primary care settings. 
Weiller et al. (1996) reported a 4.9% 1-month prevalence rate in a Paris sample of consecutive 
primary care attenders, using CIDI/DSM-III-R as part of the WHO Collaborative Study of 
Psychological Disorders in primary care. This French study showed no preponderance of 
women among individuals with social phobia in this clinical setting.  
 
4.2. Incidence, age of onset and course  
 
From an EU and international perspective, there is a lack of incidence studies. Only one EU-
based study, the EDSP (Early Developmental Stages of Psychopathology; see Lieb et al., 
2000a) provides incidence data for social phobia. This limits the degree to which firm 
conclusions can be drawn about age-related peak periods of risk of onset and to which 
estimates across the full lifespan can be derived. Social phobia is undoubtedly an early onset 
disorder in the majority of cases. Fairly stable across studies, the age of onset is reported in 
the range between 12 and 16.6 years (Wittchen et al., 1999a; Faravelli et al., 2000; Degonda 
and Angst, 1993; Schneier et al., 1992; Lépine and Lellouch, 1995; DeWit et al., 1999). When 
prevalence rates are differentiated by age group, they are generally found to decrease slightly 
across age groups (Bijl et al., 1998; Jacobi et al., 2004; Lépine and Lellouch, 1995). The onset 
of social phobia after the age of 25 seems to be rare (Wittchen et al., 1999a; see Fig. 1), but it 
might be premature to state that social phobia almost never occurs at higher ages for the first 
time.  
 
Social phobia is generally regarded as a chronic condition. In epidemiological as well as in 
clinical studies, a duration of 10 and more years is frequently reported (Perugi et al., 1990; 
Davidson et al., 1993). Data from longitudinal studies point to a lower stability when only 
cases meeting all diagnostic criteria are considered (Müller, 2002; Degonda and Angst, 1993), 
but stability rates are rather high again when subthreshold cases are included (Merikangas et 
al., 2002; Müller, 2002). Thus, the course of social phobia seems to be characterized by 
oscillations around the diagnostic threshold. Incidence was found to be 2.8% over a 42-month 
interval (Müller, 2002) in the prospective longitudinal EDSP study with a sample of 3021 
adolescents and young adults (age 14–24). About half of the incident cases had a history of 
social fears at baseline.  
 
4.3. Gender differences and sociodemographic correlates  
 
Consistent with studies from other regions of the world, gender differences have been 
documented, with women being more frequently affected by social phobia than men 
(Davidson et al., 1993; Degonda and Angst, 1993; Faravelli et al., 2000; Lépine and Lellouch, 
1995; Magee et al., 1996; Meyer et al., 2000; Schneier et al., 1992; Wittchen et al., 1999a, 
2000a,b). Odds ratios range between 1.5 and 2.2. There is an ongoing discussion whether the 
gender difference in social phobia is less pronounced than in other anxiety disorders. In 
clinical samples, usually no gender differences or even slightly higher rates for men have been 
reported (Rapee et al., 1988; Solyom et al., 1986; Heimberg and Juster, 1995), and it is 
assumed that gender roles and social expectations play a significant role in explaining the 
heightened helpseeking behaviour found in male patients (e.g., Weinstock, 1999; Turk et al., 
1998). Other sociodemographic correlates are poor financial situation, low social class, single 
or unmarried status, unemployment and poor education (Degonda and Angst, 1993; Wittchen 
et al., 1999a; Müller, 2002), but it remains unclear whether those factors are antecedents or 
consequences of social phobia.  
 
4.4. Comorbidity – associations with other mental disorders  
 
Comorbidity in social phobia seems to be the rule rather than the exception, and there is first 
evidence that comorbid disorders are not only purely temporal consequences, but that they are 
rather causally linked, as indicated by some type of dose–response relation between social 
phobia and subsequent depression (Stein et al., 2001).  
 
Lifetime comorbidity has been reported to range between 69% (Schneier et al., 1992) and 
92% (Faravelli et al., 2000). In a representative sample of the German adult population (N 
=4181; Jacobi et al., 2002; Wittchen et al., 2000a) that covered a wide range of possible 
comorbid disorders, only 12% of all cases with the diagnosis of social phobia during the past 
12 months were pure; all others had at least one other mental disorder (Fehm and Jacobi, 
unpublished data). Especially depressive disorders as well as other anxiety disorders and 
substance abuse have consistently been found to be associated with social phobia (Faravelli et 
al., 2000; Bisserbe et al., 1996; Degonda and Angst, 1993; Schneier et al., 1992; Lépine and 
Lellouch, 1995; Pini et al., 1997; Magee et al., 1996; Regier et al., 1998).  
 
Inspections of the temporal patterns show that social phobia precedes the onset of major 
depression in the majority of cases (de Graaf et al., 2003; Kessler et al., 1996; Schatzberg et 
al., 1998; Weiller et al., 1996). Additionally, social phobia has been found not only to precede 
depression temporally, but also to be associated with a more malignant course of an already 
existing depression (shorter interval between two episodes, more depressive symptoms; Stein 
et al., 2001). A less pronounced temporal relation has been reported for other anxiety 
disorders, with specific phobias having their onset often before that of social phobia. Social 
phobia seems also to precede temporally alcohol abuse or dependence, but the relationship 
between social phobia and alcoholism is particularly complex (Lépine and Pélissolo, 1998).  
 
The fact that the majority of persons affected by social phobia are also affected by other 
mental disorders has given rise to some conceptual discussions. Stimulated by considerable 
evidence from longitudinal studies, one question is whether social phobia as a frequent early 
onset primary disorder may be regarded as a risk factor for secondary complications, 
particularly the temporally secondary onset of depressive and substance use disorders 
(Sonntag et al., 2000; Stein et al., 2001).  
 
It should also be noted that the high degree of comorbidity poses significant challenges in 
estimating what proportion of disability and impairment can be clearly attributed to social 
phobia and the comorbid presentations, respectively. Similar difficulties have become 
apparent in evaluating treatment rates (see below) as well as the specificity of vulnerability 
and risk factors.  
 
4.5. Risk factors  
 
Within the developmental model of social phobia, numerous risk factors have been identified, 
but to date, only a heuristic, but not empirically proven, etiological model can be formulated. 
Some of the factors could be confirmed in prospective, longitudinal designs that allow to 
establish unambiguously the sequence of the factors (see Kraemer et al., 1997).  
 
Familial factors: The familial aggregation of social phobia has been shown in several studies 
(Reich and Yates, 1988; Fyer et al., 1993; Mannuzza et al., 1995; Stein et al., 1998); but in 
those studies, it remained unclear whether the familial clustering was specific for social 
phobia in relation to other anxiety disorders. More recent studies, covering a broader range of 
disorders assessed in parents as well as in offspring, pointed to a marked degree of specificity 
for the familial aggregation of social phobia (Lieb et al., 2000b; Merikangas et al., 2002).  
 
Two sources of familial clustering have to be considered: (1) genetic vulnerability, which has 
been supported, e.g. by twin studies (Kendler et al., 1992, 1999); (2) factors in the family 
environment, such as parental modelling and the style of child-rearing.  
 
In an experimental design, detrimental effects of mothers’ anxious reactions towards animal 
stimuli, resulting in higher anxiety levels in the children could be demonstrated (Gerull and 
Rapee, 2002). Among different facets of rearing styles, especially the combination of 
rejection and overprotection has been found to be associated with a higher risk of social 
phobia (Lieb et al., 2000b; for an overview, see Hudson and Rapee, 2000).  
 
Temperamental factors: Among possible temperamental variables, especially a child’s 
behavior characterized by withdrawal and inhibition in novel situations (behavioural 
inhibition) has been linked to the etiology of social phobia (Biederman et al., 2001; Fox and 
Henderson, 2000; Hayward et al., 1998; Schwartz et al., 1999; Turner et al., 1996). However, 
there are many methodological problems such as the retrospective design of some studies, the 
low stability of behavioural inhibition, and sample biases that hamper the interpretation of 
those studies (see Neal and Edelmann, 2003, for a critical review). In adults, social phobia 
with or without comorbid depression has been found to be significantly associated with very 
marked inhibited temperament, for instance with dramatically high harm avoidance traits and 
particularly low self-directedness levels (Pélissolo et al., 2002).  
 
4.6. Disability and quality of life  
 
Social phobia can be an extremely impairing condition, although most studies have failed so 
far to provide detailed results differentiated by gender, age groups and subtypes of the 
disorder. Available data on impairments come from different sources: clinical samples of 
selected individuals seeking for help; epidemiological samples either from the general 
population or from primary care settings; and case control studies. Case control studies 
compare individuals with social phobia with matched control groups, controlling for at least 
some possible confounding factors. As only a small portion of individuals with social phobia 
seek professional help, the generalisability of findings from clinical studies to the burden of 
social phobia in the community is limited. Many studies focused on differences among other 
clinical groups, mostly finding more similarities than differences between social phobia and 
other anxiety disorders or affective disorders with regard to associated disabilities and 
impairments (Kennedy et al., 2002; Lochner et al., 2003; Quilty et al., 2003).  
 
Epidemiological studies have addressed various areas of functioning and well-being and 
yielded consistent results that point to a profoundly negative impact of social phobia on 
quality of life. Note that individuals with social phobia, even without comorbid disorders, 
exhibit a markedly lower quality of life, which is similar to that of depressed outpatients 
(Wittchen and Beloch, 1996). Social phobia is associated with negative outcomes not only in 
social functioning, family-life, and close relationships (Lampe et al., 2003; Patel et al., 2002; 
Stein and Kean, 2000; Wittchen et al., 1999a), but also in occupational and educational 
domains. For example, social phobia is associated with early leave of school (Stein and Kean, 
2000), lower educational attainment (Katzelnick and Greist, 2001; Wittchen et al., 1999a), 
and a higher risk of being unemployed (Patel et al., 2002; Lampe et al., 2003). Moreover, 
individuals with social phobia are significantly more often engaged in jobs below their level 
of qualification (Bruch et al., 2003; Katzelnick and Greist, 2001). Some studies could 
demonstrate a linear association between the severity of the disorder (e.g. number of 
situations affected by social fears) and diverse indicators of impairment (Stein et al., 2000). In 
a recent clinical study, 771 patients with DSM-IV social phobia have been examined with the 
Various Impact of Social Anxiety disorder (VISA) scale and the clinical estimate of trained 
psychiatrists. The results showed that a professional, social, and medical burden can be 
specifically attributed to social phobia, independently of comorbid disorders (Pélissolo et al., 
2004).  
 
Disability days: The ESEMed study group (ESEMeD/MHEDEA 2000 Investigators, 2004b) 
interviewed 21,425 adult participants in six European countries (Belgium, France, Germany, 
Italy, the Netherlands, Spain). The index for work loss days for individuals with social phobia 
was 0.24 (95%CI 0.16–0.31), which is comparable to that of other anxiety and affective 
disorders (any anxiety disorder: 0.24, 95%CI 0.20–0.28; any affective disorder: 0.24, 95%CI 
0.20–0.28) and a lot higher than that of the comparison group with no disorder (0.03, 95%CI 
0.02– 0.04) and even higher than that of disturbing medical conditions (diabetes: 0.12, 95%CI 
0.08–0.17; heart disease: 0.18, 95%CI 0.12–0.23).  
 
In the German National Health Survey (Jacobi et al., 2002), in which a representative sample 
of 4181 adults was interviewed with the CIDI, notably higher numbers of disability days 
during the past 12 months were found among individuals with social phobia (M=34.9, 
SD=88.3) as compared to a group without mental disorders (M=9.9, SD=30.1). The high 
number seems to be due to the comorbid condition of social phobia, which, in this study, 
comprised 88% of the social phobia group (pure social phobia: M=7.4, SD=8.5; comorbid: 
M=38.8, SD=78.7; Fehm and Jacobi, in preparation).  
 
No data about early retirement attributable to social phobia and/or its consequences are 
available.  
 
4.7. Suicidality and premature death  
 
In American and European community studies, an increased risk of suicidality has been 
reported in patients with social phobia (Katzelnick et al., 2001; Lépine and Lellouch, 1995; 
Olfson et al., 2000; Schneier et al., 1992). In the French survey (Lépine and Lellouch, 1995), 
this increased incidence of suicidal ideation or suicide attempts was largely explained by the 
comorbidity with depression. But particularly in females, social phobia without depression 
was also associated with an elevated prevalence of suicidal tendencies (odds ratio for the rate 
of suicide attempts as compared with the controls: 6.1; 95%CI 1.9–19.4). Wunderlich et al. 
(1998) have reported similar results, with social phobia being significantly associated with 
suicide attempts (OR 2.2, 95%CI 2.3–8.3), but this association was not significant in a 
multivariate analysis including all major DSM-IV diagnoses.  
 
Data about/on estimates of the risk of premature death associated with social phobia are not 
available.  
 
4.8. Help-seeking  
 
Individuals with social phobia are found to live with their disorder for years or even decades 
before contacting mental health services, and the portion of affected individuals seeking 
professional help is low. Especially non-comorbid cases are rarely in contact with the health 
care system (Patel et al., 2002; Schneier et al., 1992; Wittchen et al., 1999a). In contrast, the 
case control study by Wittchen et al. (2000b) revealed no difference between pure, comorbid 
and even subthreshold cases with regard to quality of life and psychiatric service use.  
 
When individuals with social phobia are compared to other anxiety or affective disorders, 
they show comparably low rates of help-seeking behaviour (Bijl and Ravelli, 2000; Issakidis 
and Andrews, 2002; Issakidis et al., 2004; Patel et al., 2002; Schneier et al., 1992; Wittchen et 
al., 1999a). Several studies indicate that mental health services will not be called on until 
secondary problems such as depression or problematic substance use occur (Magee et al., 
1996; Wittchen et al., 1999a).  
 
Social phobia is still rarely detected by primary care physicians (Weiller et al., 1996) and even 
when the diagnosis is made correctly, the portion of cases receiving an empirically validated 
treatment is still low, as shown in Fig. 2 (data from Wittchen, 2000b).  
 
Apart from this data and studies conducted in American countries, little is known about the 
proportion of social phobia that is diagnosed and treated in either primary care or the specialty 
sector with drugs and/or psychological methods with established efficacy.   
 
4.9. Intervention  
 
To date, a range of psychological as well as pharmacological treatment approaches has been 
presented. The effectiveness of cognitive-behavioural interventions has been shown in 
numerous studies and already five metaanalytic reviews have been conducted (Fedoroff and 
Taylor, 2001; Feske and Chambless, 1995; Gould et al., 1997; Ruhmland and Margraf, 2001; 
Taylor, 1996). Effect sizes around 1.0 have been reported for integrated CBT and single 
components of it (e.g. only exposure, only cognitive restructuring). Even though the empirical 
evidence appears conclusive, it should be mentioned that all meta-analyses used different 
inclusion criteria and different effect size calculation procedures.  
 
Among the pharmacological approaches, selective serotonin reuptake inhibitors (SSRIs) have 
been named as the first-line choice of treatment (Bandelow, 2002; Blanco et al., 2003; 
Davidson, 2003). Positive effects on the symptomatology have also been shown for other 
substances such as benzodiazepines, serotonin-norepinephrine reuptake inhibitors (SNRI) and 
monoamine oxidase inhibitors.  
 
Although psychotherapy as well as pharmacological interventions have proven to be effective, 
there still are no conclusive empirical data with regard to the combination of both treatments. 
The additive effects of two effective treatments cannot be automatically assumed. It was 
recently reported that combining fluoxetine with cognitive-behavioural therapy did not yield 
further improvement compared with the monotherapies (Davidson et al., 2004).  
 
The rather low response rate seems even more problematic. For example, according to 
Davidson (2003), only 35– 65% of the patients receiving pharmacological treatment are 
regarded as responders.  
 
Coming back to everyday life, social phobia is known to be associated with specific treatment 
barriers such as problems with clinical detection of the diagnoses, financial barriers, 
uncertainty over where to go for help, and fear of what others might think or say (Weiller et 
al., 1996; Olfson et al., 2000). In fact, although access to the health care system is more easily 
available to European than to US or Canadian citizens and is accessed to a higher degree, 
there is still a substantial proportion of individuals not being identified or not being 
sufficiently treated. Olfson et al. (2000) suggested that care access may be enhanced through 
raised public awareness of local services, the reduction of the psychological and financial 
burden of entering psychotherapy and increased health care professionals’ awareness of the 
clinical and social significance of social phobia.  
 
4.10. Cost and burden indicators  
 
To date, no methodologically sound studies have provided estimates about the monetary costs 
of social phobia (Löthgren, 2004). However, high levels of unemployment, absenteeism from 
work, financial dependence on the state, use of prescribed medications, drug dependency, etc., 
in patients with social phobia suggest significant societal costs (Lécrubier et al., 2000; Patel et 
al., 2002). As an example, a community study in the US showed that 22.3% of the participants 
with pure generalized social phobia received financial disability or welfare benefits, as 
compared to 10.6% in controls (Schneier et al., 1992).  
 
5. Discussion  
 
Our aim was to review the European prevalence of social phobia as defined by modern 
diagnostic criteria and to highlight epidemiological data of importance for the understanding 
of this disabling disorder. The main outcome was that, even though a total of 23 studies on 
prevalence were located, only a limited number of EU countries have actually examined this 
condition. This makes it difficult to draw firm conclusions about the EU-wide total prevalence 
and burden. However, the relative consistency of the available data does lead to the following 
statements:  
 
Social phobia is a common disorder with a median lifetime prevalence of 6.65% and a high 
12-month prevalence of 2–3% when modern diagnostic criteria are applied. The difference 
between lifetime and 12-month risk might indicate a considerable variability in the natural 
course of this condition. The distribution of social phobia varied considerably across the 
countries surveyed, even when nations that are culturally and geographically close are 
compared. For instance, prevalence rates were lower in Finland than in its Scandinavian 
neighbours Norway and Sweden. However, due to design and instrument differences, it is 
premature to conclude that there is a substantial cultural or cross-national variation. Similar 
caution is also warranted with regard to the recent estimates of the pan- European ESEMeD 
study (ESEMeD/MHEDEA 2000 Investigators, 2004a), which appear to be lower than 
previous estimates. As noted by the principal investigator (WHO World Mental Health 
Survey Consortium, 2004), these preliminary (not peer reviewed) estimates should be treated 
with caution because there are obviously major design (sampling, stratification, missing items 
imputations leading to an underestimation) and technical complications that make 
interpretations difficult. Furthermore, these findings were based on diagnostic criteria and an 
instrument for which, at the time of the study, no reliability and validity were established and 
that used entirely new impairment and disability conventions (Wittchen and Jacobi, 2005).  
 
Social phobia has its onset in adolescence, and it is highly persistent. Beside a marked 
reduction in diverse indicators of quality of life, everyday functioning is severely reduced not 
only in social, but also in educational and occupational domains. Social phobia is associated 
with higher risks of suicide and of developing other psychopathology. It has to be confirmed 
through future research whether the comorbid conditions are causal consequences or mere 
associations resulting from joint underlying factors. The first interpretation–if confirmed–
would have considerable impact on early screening and early intervention of secondary 
complication as well as on prevention.  
 
Another challenge lies in the improvement of access to the health care system both on the side 
of patients and on that of caregivers through optimising, for example, the detection rates of 
social phobia. As a first step, data on pathways of individuals with social phobia to mental 
health services are urgently needed to provide starting points for effective structural 
interventions.    
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